U.S. markets close in 3 hours
  • S&P 500

    3,939.31
    -1.95 (-0.05%)
     
  • Dow 30

    33,635.16
    +38.82 (+0.12%)
     
  • Nasdaq

    10,978.69
    -36.20 (-0.33%)
     
  • Russell 2000

    1,813.88
    +1.31 (+0.07%)
     
  • Crude Oil

    72.92
    -1.33 (-1.79%)
     
  • Gold

    1,794.40
    +12.00 (+0.67%)
     
  • Silver

    22.85
    +0.52 (+2.33%)
     
  • EUR/USD

    1.0521
    +0.0052 (+0.49%)
     
  • 10-Yr Bond

    3.4480
    -0.0650 (-1.85%)
     
  • GBP/USD

    1.2224
    +0.0091 (+0.75%)
     
  • USD/JPY

    136.3350
    -0.6250 (-0.46%)
     
  • BTC-USD

    16,812.46
    -165.73 (-0.98%)
     
  • CMC Crypto 200

    394.76
    -7.27 (-1.81%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,686.40
    -199.47 (-0.72%)
     

Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids science, is pleased to report an additional milestone with respect to Innocan patent application: PCT application WO2021/240505 that claims Cannabinoids Based Topical Compositions for Treatment of Psoriasis of the Scalp, reached national phase.

Entering the national phase is one of the major milestones in a patent lifecycle. By entering US and EU, Innocan will have the possibility to protect its pharmaceutical products in the major business countries in the world upon the patent grant.

This milestone represents the continued efforts by Innocan to provide patent protection to its products in alignment with its business goals and according to patent law requirements.

Psoriasis of the scalp is a skin disorder associated with any of the following symptoms: dry scalp, scaly patches on the scalp, hair loss, burning, soreness and white scales. Scalp psoriasis may be difficult to treat and mostly it is currently being treated with intralesional steroids injected to the affected areas. However, such treatment is typically used in small areas of the scalp. In addition, steroid use is often associated with side effects. Innocan's composition presents the potential for effective treatment without providing an unaesthetic appearance and without causing irritation to the scalp.

"The global psoriasis therapeutics market size was valued at USD $22.9 billion in 2021, and is projected to reach USD $55.8 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031." (September 2022, Allied Market Research)

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global LTD that focuses developing on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+15162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

Dr. Eva Reuter
Investment Relation- Germany
+46-69-1532-5857
e.reuter@dr-reuter.eu

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/139763